[{"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 69, "title": "Executive Chairman", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 7190594, "exercisedValue": 0, "unexercisedValue": 47864680}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 4616880, "exercisedValue": 0, "unexercisedValue": 15390147}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 55, "title": "Executive VP & CFO", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 3132761, "exercisedValue": 0, "unexercisedValue": 5589906}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 60, "title": "Executive VP & COO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 3510428, "exercisedValue": 5248500, "unexercisedValue": 23376292}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 54, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 4315363, "exercisedValue": 2125307, "unexercisedValue": 9617938}, {"maxAge": 1, "name": "Dr. Roopal  Thakkar M.D.", "age": 51, "title": "Executive VP of Research and Development & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Perry C. Siatis", "age": 48, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay  Narayan", "title": "Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 57, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1121841, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 5, "compensationRisk": 2, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 203.87, "open": 204.37, "dayLow": 202.32, "dayHigh": 204.73, "regularMarketPreviousClose": 203.87, "regularMarketOpen": 204.37, "regularMarketDayLow": 202.32, "regularMarketDayHigh": 204.73, "dividendRate": 6.56, "dividendYield": 0.0322, "exDividendDate": 1736899200, "payoutRatio": 2.1359, "fiveYearAvgDividendYield": 4.16, "beta": 0.618, "trailingPE": 70.92335, "forwardPE": 16.822313, "volume": 4360183, "regularMarketVolume": 4360183, "averageVolume": 4719015, "averageVolume10days": 5893790, "averageDailyVolume10Day": 5893790, "bidSize": 800, "askSize": 800, "marketCap": 359538491392, "fiftyTwoWeekLow": 135.85, "fiftyTwoWeekHigh": 207.32, "priceToSalesTrailing12Months": 6.4743214, "fiftyDayAverage": 194.1378, "twoHundredDayAverage": 177.92665, "trailingAnnualDividendRate": 6.2, "trailingAnnualDividendYield": 0.030411536, "currency": "USD", "enterpriseValue": 417363263488, "profitMargins": 0.09222999, "floatShares": 1763199653, "sharesOutstanding": 1766339968, "sharesShort": 16183592, "sharesShortPriorMonth": 17793512, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0092, "heldPercentInsiders": 0.00093000004, "heldPercentInstitutions": 0.73477, "shortRatio": 3.56, "shortPercentOfFloat": 0.0092, "bookValue": 3.838, "priceToBook": 53.035435, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.122, "netIncomeToCommon": 5079000064, "trailingEps": 2.87, "forwardEps": 12.1, "pegRatio": 2.87, "enterpriseToRevenue": 7.516, "enterpriseToEbitda": 15.369, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "gmtOffSetMilliseconds": -18000000, "currentPrice": 203.55, "targetHighPrice": 240.0, "targetLowPrice": 170.0, "targetMeanPrice": 209.36, "targetMedianPrice": 211.59, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 13157000192, "totalCashPerShare": 7.449, "ebitda": 27156000768, "totalDebt": 70938001408, "totalRevenue": 55532998656, "debtToEquity": 1039.994, "revenuePerShare": 31.41, "earningsGrowth": -0.12, "revenueGrowth": 0.038, "grossMargins": 0.7014, "ebitdaMargins": 0.48901, "operatingMargins": 0.3397, "financialCurrency": "USD", "trailingPegRatio": 0.4751, "__fetch_time": "2024-11-04"}]